Freenome, Inc. completed a business combination with Perceptive Capital Solutions Corp (PCSC) on July 20, 2026, resulting in the domestication of PCSC as a Delaware corporation. The transaction involved the merger of Merger Sub I and Merger Sub II into Freenome, with Freenome surviving as a wholly-owned subsidiary of PCSC, which subsequently changed its name to Freenome, Inc. The company received approximately $310.3 million in gross proceeds, including $240.0 million from a concurrent PIPE investment. Following the closing, Freenome's common stock began trading on the Nasdaq Capital Market under the symbol FRNM. Freenome is a healthcare company specializing in cancer detection and diagnostics.
